Understand the source comparison
Best Research Peptides for Frailty Research: Mechanism Comparison
GHRP-2 Ghrelin receptor agonist; stimulates pulsatile GH release GH/IGF-1 axis Muscle mass, grip strength 100–300 mcg SC, 1–2x daily Strong evidence for muscle preservation; requires consistent dosing to maintain GH pulse pattern MK-677 (Ibutamoren) Oral ghrel
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- GHRP-2
- Ghrelin receptor agonist; stimulates pulsatile GH release
- GH/IGF-1 axis
- Muscle mass, grip strength
- 100–300 mcg SC, 1–2x daily
- Strong evidence for muscle preservation; requires consistent dosing to maintain GH pulse pattern
- MK-677 (Ibutamoren)
- Oral ghrelin mimetic; sustained GH elevation
- Lean body mass, physical function
- 10–25 mg PO daily (human equivalent)
- Longer half-life simplifies dosing; human trials show functional gains in elderly populations
- MOTS-c
- Mitochondrial-derived peptide; AMPK activator
- Cellular energy metabolism
- Exercise capacity, fatigue resistance
- 5–15 mg/kg SC, 3x weekly
- Targets energy deficit rather than muscle mass; best for metabolic frailty phenotypes
- BPC-157
- Multi-pathway tissue repair; angiogenesis and inflammation modulation
- Regenerative signaling
- Systemic inflammation, wound healing
- 200–500 mcg SC daily
- Limited direct frailty research; strongest evidence in injury recovery and inflammation models